Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.
BACKGROUND: Stereotactic body radiation therapy (SBRT) is the standard of care for early-stage, medically inoperable non-small-cell lung cancer (NSCLC). FUNDING: US National Institutes of Health, US National Cancer Institute, and Genentech.
BACKGROUND: Stereotactic body radiation therapy (SBRT) is the standard of care for early-stage, medically inoperable non-small-cell lung cancer (NSCLC). FUNDING: US National Institutes of Health, US National Cancer Institute, and Genentech.
What the study was
- Study design
- RCT
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- Lancet
Why it surfaced
Matched watchlist topic(s): Sentinel. Study design: RCT. Score 7/10. 🟢 Near-term implementable finding.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.